PCSK9 and metabolic syndrome: As CKD patients remain a population with unmet needs in the management of dyslipidemia and cardiovascular morbidity and mortality, PCSK9 might be an interesting therapeutic target for the treatment of atherosclerotic disease beyond LDL-C regulation.